(NASDAQ: LYRA) Lyra Therapeutics's forecast annual revenue growth rate of 181.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.16%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Lyra Therapeutics's revenue in 2025 is $1,471,000.On average, 2 Wall Street analysts forecast LYRA's revenue for 2025 to be $78,876,466, with the lowest LYRA revenue forecast at $53,675,271, and the highest LYRA revenue forecast at $104,077,660. On average, 1 Wall Street analysts forecast LYRA's revenue for 2026 to be $739,671,422, with the lowest LYRA revenue forecast at $739,671,422, and the highest LYRA revenue forecast at $739,671,422.
In 2027, LYRA is forecast to generate $2,320,473,622 in revenue, with the lowest revenue forecast at $2,320,473,622 and the highest revenue forecast at $2,320,473,622.